quinoxalines has been researched along with HIV in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arends, JE; Brinkman, K; Burger, DM; Dofferiiof, ASM; Reiss, P; Rijnders, B; Smit, C; Smolders, EJ; T M M de Kanter, C; van der Valk, M | 1 |
| Sulkowski, MS | 1 |
| Liu, W; Lovell, S; Mensa, FJ; Pilot-Matias, T | 1 |
| Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Mangin, E; Marshall, W; Martinho, M; Panebianco, D; Talaty, JE; Valesky, R; Yeh, WW; Zhu, Y | 1 |
| Chacko, S; Mathew, T; Olah, GA; Panja, C; Prakash, GK; Vaghoo, H; Venkat, A | 1 |
| Loriga, M; Paglietti, G; Piras, S; Sanna, P | 1 |
| Duval, X | 1 |
| Ansari, AA; Heeney, JL; Mori, K; Rosenwith, B; Rübsamen-Waigmann, H; Sawada, S; Sugama, K; Uberla, K; Villinger, F; Yamazaki, S; Yasutomi, Y | 1 |
| Pieribone, V | 1 |
| Carta, A; La, CP; Loddo, R; Loriga, M; Sanna, P; Setzu, MG | 1 |
1 review(s) available for quinoxalines and HIV
| Article | Year |
|---|---|
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Fibrosis; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Sulfonamides; Treatment Outcome | 2019 |
2 trial(s) available for quinoxalines and HIV
| Article | Year |
|---|---|
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
Topics: Adult; Antiviral Agents; Area Under Curve; Benzofurans; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; HIV; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2019 |
Los Angeles, New York, Stanford University: HBY 097, new drug may weaken HIV.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV; HIV Reverse Transcriptase; Humans; Los Angeles; Mutation; New York; Quinoxalines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; San Francisco | 1995 |
8 other study(ies) available for quinoxalines and HIV
| Article | Year |
|---|---|
Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
Topics: Adult; Aged; Aged, 80 and over; Amides; Anti-Retroviral Agents; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Combined Modality Therapy; Cross-Sectional Studies; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Imidazoles; Middle Aged; Quinoxalines; Retrospective Studies; Ritonavir; Sulfonamides; Young Adult | 2017 |
The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
Topics: Amides; Benzofurans; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Hepacivirus; HIV; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Quinoxalines; Ribavirin; Sexual and Gender Minorities; Sulfonamides | 2019 |
Gallium (III) triflate-catalyzed synthesis of heterocycles: quinoxalines, 1,5-benzodiazepines and their fluorinated derivatives.
Topics: Benzodiazepines; Catalysis; Halogenation; HIV; HIV Reverse Transcriptase; Humans; Mesylates; Quinoxalines; Reverse Transcriptase Inhibitors | 2009 |
Quinoxaline chemistry. Part 7. 2-[aminobenzoates]- and 2-[aminobenzoylglutamate]-quinoxalines as classical antifolate agents. Synthesis and evaluation of in vitro anticancer, anti-HIV and antifungal activity.
Topics: Aminobenzoates; Anti-HIV Agents; Antifungal Agents; Antineoplastic Agents; Candida albicans; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Glutamates; HIV; Humans; Microbial Sensitivity Tests; Molecular Structure; Quinoxalines; Tumor Cells, Cultured | 1997 |
[The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
Topics: Alkynes; Animals; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Time Factors; Uracil; Viral Load | 2000 |
Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulti
Topics: Animals; Antibodies, Viral; Antiviral Agents; COS Cells; HIV; HIV Reverse Transcriptase; Humans; Macaca mulatta; Male; Quinoxalines; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocytes, Cytotoxic; Time Factors; Viremia | 2000 |
Overcoming resistance to reverse transcriptase inhibitors.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Microbial; HIV; Humans; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; RNA, Viral; Virus Replication | 1995 |
Synthesis and evaluation for biological activity of 3-alkyl and 3-halogenoalkyl-quinoxalin-2-ones variously substituted. Part 4.
Topics: Anti-Infective Agents; Antifungal Agents; Antiviral Agents; Cell Line; Dose-Response Relationship, Drug; HIV; Humans; Linear Models; Microbial Sensitivity Tests; Quinoxalines; Structure-Activity Relationship | 2002 |